Suppliers / Kiyan Pharma

Kiyan Pharma

Japan Updated 9 July 2026

Kiyan Pharma is an API manufacturer based in Japan. It holds one active US drug master file. Its most recent recorded inspection, by US FDA, closed on 26 February 2016 as VAI.

1
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 26 February 2016 VAI US FDA
  • 19 October 2012 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Japan, Japan 3004778932

What they file, and where

Molecule Regulators Docs
Mycophenolic Acid US FDA 1

Also appears on these molecule pages

Mycophenolic Acid API

Questions about Kiyan Pharma

Does Kiyan Pharma hold a US DMF or a CEP?
Kiyan Pharma holds 1 active US drug master file. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Kiyan Pharma FDA-registered?
One site operated by Kiyan Pharma carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Kiyan Pharma's last inspection go?
The most recent inspection on record closed on 26 February 2016 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 2 inspections are on file.
Where does Kiyan Pharma manufacture?
1 registered site is on record, in Japan (Japan). Every site is listed on this page with the register it came from.
What does Kiyan Pharma make?
1 molecule is on record against Kiyan Pharma, including Mycophenolic Acid. Each links through to that molecule's full manufacturer list.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Kiyan Pharma comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 26 February 2016.

Comparable suppliers

Solara Active Pharma Sciences shares 1 molecule Biocon shares 1 molecule Apotex shares 1 molecule Dasami Lab shares 1 molecule Formosa Laboratories shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability